Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03117309
Title Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael B. Atkins, MD
Indications

renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Yale University, Yale Cancer Center Active, not recruiting New Haven Connecticut 06520 United States Details
Georgetown University Recruiting Washington District of Columbia 20057 United States Details
Winship Cancer Institute of Emory University Recruiting Atlanta Georgia 30322 United States Details
Northwestern University Feinberg Schooll Of Medicine Recruiting Chicago Illinois 60611 United States Details
University of Illinois Cancer Center Recruiting Chicago Illinois 60612 United States Details
Beth Isreal Deaconess Medical Center Recruiting Boston Massachusetts 02215 United States Details
Hackensack University Medical Center Completed Hackensack New Jersey 07601 United States Details
Columbia University Recruiting New York New York 10032 United States Details
Cleveland Clinic Recruiting Cleveland Ohio 44915 United States Details
Univeristy of Pennsylvania Recruiting Philadelphia Pennsylvania 19104 United States Details
Fox Chase Cancer Center Recruiting Philadelphia Pennsylvania 19111 United States Details
University of Texas Southwestern Medical Center Recruiting Dallas Texas 75390 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field